What one share of UroGen Pharma holds
We are a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. We have developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based technology that has the potential to improve therapeutic profiles of existing drugs.
UroGen Pharma’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $3.82 |
|---|---|
| Profit | −$1.97 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$3.22 |
| Cash and investments | $1.62 |
| Debt | $3.95 |
| Book value | −$2.71 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2015 | — | −$5.88 | $0.13 | −$3.25 | — | $7.08 |
| 2016 | — | −$1.91 | $0.30 | $1.52 | — | $7.07 |
| 2017 | — | −$2.14 | $0.03 | −$1.01 | — | $4.98 |
| 2018 | — | −$4.80 | $0.04 | −$2.41 | — | $5.56 |
| 2019 | — | −$5.12 | $0.02 | −$3.48 | — | $8.58 |
| 2020 | $0.54 | −$5.90 | $0.06 | −$4.92 | — | $4.35 |
| 2021 | $2.15 | −$4.96 | $0.03 | −$3.83 | — | $0.37 |
| 2022 | $2.82 | −$4.81 | $0.01 | −$3.85 | — | −$3.86 |
| 2023 | $2.87 | −$3.55 | $0.01 | −$2.66 | — | −$2.01 |
| 2024 | $2.11 | −$2.96 | $0.01 | −$2.26 | — | −$0.21 |
| 2025 | $2.28 | −$3.19 | $0.01 | −$3.38 | — | −$2.18 |
Common questions about UroGen Pharma
How much does one share of UroGen Pharma earn?
Over the last 12 months, UroGen Pharma lost $1.97 for each share on $3.82 of sales.
Does UroGen Pharma pay a dividend?
UroGen Pharma didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is UroGen Pharma’s book value per share?
UroGen Pharma’s book value is negative (−$2.71 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of UroGen Pharma have?
Each share of UroGen Pharma has $1.62 of cash and investments and $3.95 of debt, as of June 30, 2026.
What is UroGen Pharma’s free cash flow per share?
−$3.22 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has UroGen Pharma bought back shares?
UroGen Pharma’s share count rose about 1991% from 2015 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.